LOGO-AEGLEA-RGB_small.jpg
Aeglea BioTherapeutics Announces Proposed Public Offering
April 27, 2020 16:01 ET | Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, April 27, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as...
LOGO-AEGLEA-RGB_small.jpg
Aeglea BioTherapeutics Announces Approval of Clinical Trial Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
April 08, 2020 07:30 ET | Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, April 08, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions...
LOGO-AEGLEA-RGB_small.jpg
Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones
February 24, 2020 07:30 ET | Aeglea BioTherapeutics, Inc.
Company Expects to Complete Enrollment in Phase 3 Trial for Patients with Arginase 1 Deficiency in Third Quarter of 2020, with Topline Data Expected in First Quarter of 2021 Phase 1/2 Trial for...
LOGO-AEGLEA-RGB_small.jpg
Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
January 13, 2020 07:00 ET | Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions...
LOGO-AEGLEA-RGB_small.jpg
Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
January 06, 2020 16:05 ET | Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions...
LOGO-AEGLEA-RGB_small.jpg
Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
November 26, 2019 08:30 ET | Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions...
LOGO-AEGLEA-RGB_small.jpg
Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights
November 06, 2019 08:30 ET | Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions...
LOGO-AEGLEA-RGB_small.jpg
Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer
November 04, 2019 08:30 ET | Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions...
LOGO-AEGLEA-RGB_small.jpg
Aeglea BioTherapeutics to Present at 21st Annual H.C. Wainwright Global Investment Conference
September 05, 2019 08:30 ET | Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions...
LOGO-AEGLEA-RGB_small.jpg
Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium
September 03, 2019 06:00 ET | Aeglea BioTherapeutics, Inc.
Sustained Control of Plasma Arginine Accompanied by Clinical Response; Overall Clinical Responder Rate of 79% Management to Host Conference Call at 9:00 a.m. ET on Tuesday, September 3 AUSTIN,...